BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $879 | -23.6% | 172,961 | -10.0% | 0.01% | -12.5% |
| Q4 2023 | $1,151 | -78.3% | 192,202 | -74.4% | 0.01% | -84.3% |
| Q3 2023 | $5,310 | -37.8% | 750,053 | -38.1% | 0.05% | -26.1% |
| Q2 2023 | $8,536 | -16.2% | 1,212,547 | -0.7% | 0.07% | -17.9% |
| Q1 2023 | $10,189 | +3959.4% | 1,221,681 | +5493.3% | 0.08% | +2000.0% |
| Q4 2022 | $251 | -100.0% | 21,842 | -96.9% | 0.00% | -96.6% |
| Q3 2022 | $8,937,000 | +19.2% | 709,285 | +0.1% | 0.12% | +27.2% |
| Q2 2022 | $7,500,000 | +348.3% | 708,919 | +486.7% | 0.09% | +441.2% |
| Q4 2021 | $1,673,000 | +175.2% | 120,827 | +185.7% | 0.02% | +112.5% |
| Q3 2021 | $608,000 | -68.4% | 42,295 | -65.2% | 0.01% | -61.9% |
| Q2 2021 | $1,923,000 | +1024.6% | 121,603 | +238.1% | 0.02% | +425.0% |
| Q2 2020 | $171,000 | – | 35,969 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |